Marie Attard

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud et al. · Clinical Cancer Research · 2023 · 94 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

Éric Baudin, Bernard Goichot, Alfredo Berruti et al. · The Lancet · 2024 · 66 citations · Full text

Medicine, Oncology, Pharmacology +7

Redifferentiation of a <i> BRAF ^K601E </i> -Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment

Sophie Leboulleux, Corinne Dupuy, Ludovic Lacroix et al. · Thyroid · 2019 · 55 citations

Medicine, Nuclear Medicine, Oncology +17

Can preoperative ultrasound predict extrathyroidal extension of differentiated thyroid cancer?

Livia Lamartina, Julien Hadoux, Joanne Guerlain et al. · European Journal of Endocrinology · 2021 · 41 citations

Medicine, Oncology, Pathology +17

MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud et al. · Journal of the Endocrine Society · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +16